| Drug Name |
Buprenorphine hydrochloride |
| Drug ID |
BADD_D00311 |
| Description |
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction.[F4715,F4718] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,F4715,F4718] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet. |
| Indications and Usage |
For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N02AE01; N07BC01 |
| DrugBank ID |
DB00921
|
| KEGG ID |
D00836
|
| MeSH ID |
D002047
|
| PubChem ID |
3033050
|
| TTD Drug ID |
D06AWE
|
| NDC Product Code |
50090-1571; 59385-022; 55700-867; 59385-025; 0409-2012; 59385-021; 63275-9922; 42023-179; 0517-0725; 12496-0757; 0792-0634; 62991-1583; 38779-0888; 12578-608; 47848-007; 59385-024; 59385-027; 50383-924; 0406-2910; 50383-930; 0792-0630; 59385-023; 10920-590; 51927-0140; 62756-316; 73548-0608; 71795-1100; 49452-8253; 0406-2933; 67509-008; 0143-9246; 59385-026; 65267-104; 51927-1012; 12707-035; 53747-012; 61960-9064; 0406-3210; 57587-924; 57587-930; 51634-0608; 63629-7125 |
| Synonyms |
Buprenorphine | Buprenex | Prefin | Subutex | Buprex | Temgesic | Temgésic | 6029-M | 6029 M | 6029M | RX-6029-M | RX 6029 M | RX6029M | Buprenorphine Hydrochloride | Hydrochloride, Buprenorphine |
